Skip to main content

Continental Drift by Benjamin Grob-Fitzgibbon

Ernest Bevin cph.3b17494.jpg

I have to say right up front: I haven't read Grob-Fitzgibbon's book. Nor do I plan to. Nonetheless, his is a really cool hyphenated surname, and that at least makes him and by extension his new book worth some mention here.

The book, Continental Drift, is apparently about the drift of Great Britain's political self-image away from the continent of Europe. Chronologically, the sweep seems to be from Ernest Bevin to the present.

Bevin was the Secretary of State for Foreign Affairs under Prime Minister Attlee from 1945 to 1951. That is his photo, above. Bevin accepted the loss of India, but thought the British Empire had to compensate by holding more tightly onto its possessions in Africa and the Middle East. Bevin also hoped to encourage a united new political structure in Europe, with Britain of course to play the leading role. This would enable Britain to retain Big Three status alongside the US and USSR.  

Britain's self-image as a member of this Big Three club did not survive the Suez crisis in the mid-1950s, though, and the nature of its relationship with the rest of Europe was to take a number of twists and turns.

I have a forthcoming book review in The Federal Lawyer that will speak to related issues, from the point of view of Britain's, and Europe's, finances. That's of another book, not of Grob-Fitzgibbon's which (have I mentioned?) I have not read. I am told it is a fine work.

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…